论文部分内容阅读
目的评价磁共振三维多时相(3D FAME)动态增强新技术在原发性肝细胞癌与肝血管瘤诊断中的作用。方法对70例肝脏占位病变的病人,采用3D FAME序列加脂肪抑制及二维MR对比增强图像,并将部分结果与手术病理对照,将二者对肝癌和肝血管瘤的检出率进行比较。结果 MR二维增强检出25个肝癌病灶和43个肝血管瘤病灶,而3D FAME序列动态增强扫描检出28个肝癌病灶和47个肝血管瘤病灶。3D FAME动态增强对肝癌病灶的敏感性(87%)较二维增强(78%)更高;3DFAME动态增强对血管瘤病灶的敏感性(95%)较二维(87%)更高。结论 3D FAME动态增强较二维增强对原发性肝细胞癌与肝血管瘤的敏感性及鉴别诊断具有更大的提高,其临床应用前景更为广泛。
Objective To evaluate the role of 3D FAME dynamic enhancement in the diagnosis of primary hepatocellular carcinoma and hepatic hemangiomas. Methods 70 patients with liver lesions were treated with 3D FAME sequence plus fat suppression and two-dimensional contrast-enhanced MR images. The results were compared with the surgical pathology, and the detection rate of both liver cancer and hepatic hemangioma was compared . Results Two-dimensional MR imaging enhanced the detection of 25 liver cancer lesions and 43 lesions of hepatic hemangiomas, while the 3D FAME sequence dynamic enhanced scanning detected 28 liver cancer lesions and 47 hepatic hemangioma lesions. 3D FAME dynamic enhancement was more sensitive to liver cancer lesions (87%) than 2D enhancement (78%); 3DFAME dynamic enhancement was more sensitive to hemangioma lesions (95%) than 2D (87%). Conclusion The dynamic enhancement of 3D FAME is more promising than the two-dimensional enhancement in the sensitivity and differential diagnosis of primary hepatocellular carcinoma and hepatic hemangioma. The clinical application of 3D FAME is more extensive.